Re-biopsy status among Chinese non-small-cell lung cancer patients who progressed after icotinib therapy

OBJECTIVE: Acquired T790M mutations account for 50%–60% of tyrosine kinase inhibitor (TKI)-resistant mechanisms in EGFR mutation-positive (m+) non-small-cell lung cancer (NSCLC) patients, and re-biopsy is recommended to detect these mutations. We investigated the re-biopsy status and the T790M incid...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Onco Targets Ther
Autors principals: Wang, Hanping, Zhang, Li, Si, Xiaoyan, Zhang, Xiaotong, Wang, Mengzhao
Format: Artigo
Idioma:Inglês
Publicat: Dove Medical Press 2018
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6208793/
https://ncbi.nlm.nih.gov/pubmed/30464499
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S174075
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars